Here is a roundup of high developments within the biotech house during the last 24 hours.
Scaling The Peaks
(Biotech Shares Hitting 52-week highs on March 3)
- Acceleron Pharma Inc (NASDAQ: XLRN)
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
- Destiny Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter outcomes)
- Forty Seven Inc (NASDAQ: FTSV)
- IGM Biosciences Inc (NASDAQ: IGMS)
- Inovio Prescription drugs Inc (NASDAQ: INO)( introduced an accelerated timeline for COVID-19 vaccine growth)
- Repro-Med Methods, Inc. (NASDAQ: KRMD)
- SpringWorks Therapeutics Inc (NASDAQ: SWTX)
- Zynex Inc. (NASDAQ: ZYXI)
Down In The Dumps
(Biotech Shares Hitting 52-week lows on March 3)
- ADDEX THERAPEUT/ADR (NASDAQ: ADXN)
- Akorn, Inc. (NASDAQ: AKRX)
- Aldeyra Therapeutics Inc (NASDAQ: ALDX)
- ANI Prescription drugs Inc (NASDAQ: ANIP)
- Evolus Inc (NASDAQ: EOLS)
- EXACT Sciences Company (NASDAQ: EXAS)
- HTG Molecular Diagnostics Inc (NASDAQ: HTGM)
- Midatech Pharma PLC-ADR (NASDAQ: MTP)(started buying and selling on a reverse cut up adjusted foundation)
- Mylan NV (NASDAQ: MYL)
- Neuronetics Inc (NASDAQ: STIM)(introduced its fourth-quarter outcomes)
- Passage Bio Inc (NASDAQ: PASG)(IPOed final week)
- STRATA Pores and skin Sciences Inc (NASDAQ: SSKN)
- SurModics, Inc. (NASDAQ: SRDX)
- Tetraphase Prescription drugs Inc (NASDAQ: TTPH)
- TransMedics Group Inc (NASDAQ: TMDX)(reported its fourth-quarter outcomes)
- VIVUS, Inc. (NASDAQ: VVUS)
- Xeris Prescription drugs Inc (NASDAQ: XERS)
See Additionally: Consideration Biotech Buyers: Mark Your Calendar For These March PDUFA Dates
Shares In Focus Takeda To Develop COVID-19 Therapies
Takeda Pharmaceutical Co Ltd (NYSE: TAK) stated it’s initiating the event of an anti-SARS-CoV-2 polyclonal hyperimmune globulin to deal with high-risk people with the viral an infection. Hyperimmune globulins are plasma-derived therapies that had beforehand confirmed its efficacy in treating extreme acute viral respiratory infections.
The corporate added it’s also learning its at the moment marketed and pipeline merchandise to see whether or not they’re efficient therapies for contaminated sufferers.
Individually, the corporate stated it has accomplished its beforehand introduced sale of portfolio of choose merchandise to STADA for $660 million.
In pre-market buying and selling Wednesday, Takeda shares have been including 3.94% to $18.20.
Vir, Alnylam Expands Collaboration To Develop siRNA Therapies For COVID-19
Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Prescription drugs, Inc. (NASDAQ: ALNY) introduced an enlargement to their present collaboration to incorporate the event and commercialization of RNAi therapeutics in opposition to COVID-19. The settlement supplies for Vir utilizing Alnylam’s current advances in lung supply of novel conjugates of siRNA together with its infectious illness experience to develop one or some siRNAs to deal with COVID-19 and different coronaviruses as properly.
In premarket buying and selling Wednesday, Vir share have been rallying 14.72% to $47 and Alnylam was edging up 0.41% to $111.88.
Mallinckrodt Reviews Constructive End result Evaluation of Acthar Gel In Immune-mediated Ailments
Mallinckrodt PLC (NYSE: MNK) introduced findings from a retrospective medical report evaluation, which assessed follow patterns and outcomes of Acthar Gel within the remedy of immune-mediated ailments rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis, which confirmed throughout all of the three affected person populations, signs improved with Acthar Gel.
In premarket buying and selling Wednesday, the shares have been advancing 7.99% $3.38.
Acadia’s Rett Syndrome Investigational Drug Will get Uncommon Pediatric Designation
ACADIA Prescription drugs Inc. (NASDAQ: ACAD) and Neuren Pharma stated the FDA has granted Uncommon Pediatric Illness designation to trofinetide for the remedy of Rett syndrome, a critical and uncommon neurological dysfunction.
Upon approval of a product with the designation, the sponsor is eligible to obtain a Precedence Assessment Voucher, which can be utilized to acquire FDA approval of an NDA for one more product in an expedited interval of six months.
Acadia shares have been up 2.41% to $42.99 in after-hours buying and selling.
Morphosys’ Licensing Settlement With Incyte For Lymphoma Drug Will get Antitrust Clearance
Morphosys Ag (NASDAQ: MOR) and Incyte Company (NASDAQ: INCY) stated their joint collaboration and license settlement for additional growth and international commercialization of Morphosys’ investigational compound tafasitamab has acquired antitrust clearance and turns into efficient Tuesday.
The regulatory milestone triggers a $750 million upfront fee by Incyte to Morphosys, and in addition Incyte’s fairness funding of $150 million into MorphoSys throughout the outlined timelines.
The PDUFA date for the BLA for tafasitamab together with lenalidomide for the remedy of sufferers with relapsed or refractory diffuse massive B-cell lymphoma is Aug. 30.
Ultragenyx CFO To Step Down
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stated Shalini Sharp will step down as CFO and EVP, efficient Sept. 2. The corporate stated it’ll provoke a seek for a successor.
Precise Sciences Buys Two Most cancers Diagnostics Firms
Precise Sciences stated it has accomplished its acquisition of Paradigm Diagnostics and Viomics, two privately held corporations, which offer a differentiated late-stage remedy choice take a look at and deep competencies in sequencing and biomarker discovery.
View extra earnings on TAK
The corporate expects the acquisition to increase its lab testing and analysis and growth capabilities.
J&J Makes Regulatory Submission For Approval of A number of Sclerosis Drug In Europe
Johnson & Johnson’s (NYSE: JNJ) Janssen unit introduced it submitted a Advertising and marketing Authorization Software to EMA, looking for approval for ponesimod for the remedy of grownup sufferers with relapsing a number of sclerosis.
DURECT Company (NASDAQ: DRRX) reported fourth-quarter web revenues of $10.69 million in comparison with $3.63 million final 12 months. The web loss per share narrowed from 5 cents to 2 cents, consistent with the consensus estimate.
The inventory jumped 12.21% to $1.93 in after-hours buying and selling.
Menlo Therapeutics Inc’s (NASDAQ: MNLO), which has agreed to be purchased by Foamix Prescription drugs Ltd (NASDAQ: FOMX), reported a wider lack of 89 cents per share in comparison with the year-ago lack of 76 cents per share and the consensus loss estimate of 83 cents per share.
Updating on the pending merger, Menlo stated it expects it to shut March 9.
The inventory jumped 23.64% to $3.40 in after-hours buying and selling.
Voyager Therapeutics Inc (NASDAQ: VYGR) reported fourth quarter revenues of $32.67 million in comparison with $2.01 million a 12 months in the past. The web loss per share narrowed from 77 cents to 34 cents. Analysts had estimated a lack of 81 cents per share. The corporate stated it expects its money reserves in addition to receivables to be enough to satisfy its projected working bills and capex into mid-2022.
The inventory gained 6.22% to $12.30 in after-hours buying and selling.
Vivus reported fourth-quarter complete revenues of $17.25 million and a lack of 61 cents per share, narrower than the 68 cents per share loss anticipated by analysts.
The inventory rose 8.98% to $1.82 in after-hours buying and selling.
Zogenix, Inc. (NASDAQ: ZGNX) stated it has priced its underwritten public providing of 8.52 million shares at $23.50 per share. The corporate expects to boost gross proceeds of $200.2 million from the providing. The providing is predicted to shut on or about March 6.
The corporate stated it expects to make use of the web proceeds for the potential commercialization of Fintepla for the remedy of Dravet syndrome, amongst different issues.
The inventory fell 3.69% to $24 in after-hours buying and selling.
On The Radar Earnings
- AMAG Prescription drugs, Inc. (NASDAQ: AMAG) (earlier than the market open)
- Recro Pharma Inc (NASDAQ: REPH) (earlier than the market open)
- PPD Inc (NASDAQ: PPD) (earlier than the market open)
- Axonics Modulation Applied sciences Inc (NASDAQ: AXNX) (after the shut)
- Orthopediatrics Corp (NASDAQ: KIDS) (after the shut)
- Opiant Prescription drugs Inc (NASDAQ: OPNT) (after the shut)
See extra from Benzinga
© 2020 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.